Drug Trial Radar · NCT05450965
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Jul 19, 2022
Primary completion
Aug 31, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- University of Maryland, BaltimoreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cardiff Oncology; National Cancer Institute (NCI)
- First posted
- Jul 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Conditions
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
Interventions
OnvansertibDrug
Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 42 months (cohort)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.